Premium
In vivo effects of the 5‐HT 6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate
Author(s) -
Dawson L A,
Nguyen H Q,
Li P
Publication year - 2000
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0703288
Subject(s) - microdialysis , dopamine , striatum , glutamate receptor , medicine , neurochemical , endocrinology , chemistry , basal ganglia , neurotransmitter , extracellular , receptor antagonist , antagonist , biology , neuroscience , receptor , biochemistry , central nervous system
Although the 5‐HT 6 receptor subtype was identified some 5 years ago, very little is known about its function within the brain. Here we demonstrate, for the first time, the neurochemical effects of a selective 5‐HT 6 receptor ligand. Using in vivo microdialysis in the freely moving rat, we evaluated the effects of the selective 5‐HT 6 receptor antagonist SB‐271046 by simultaneous measurement of 5‐hydroxytryptamine (5‐HT), dopamine (DA), noradrenaline (NA), glutamate and aspartate from the striatum and frontal cortex. SB‐271046 did not alter basal levels of 5‐HT, DA and NA in either brain region. Similarly, there was no change basal levels of either of the excitatory amino acids within the striatum. In contrast, administration of SB‐271046 (10 mg kg −1 s.c.) produced a significant ( P <0.05), tetrodotoxin‐dependent, increase in extracellular levels of both glutamate and aspartate within the frontal cortex, reaching maximum values of 375.4±82.3 and 215.3±62.1% of preinjection values, respectively. British Journal of Pharmacology (2000) 130 , 23–26; doi: 10.1038/sj.bjp.0703288